全文获取类型
收费全文 | 2274篇 |
免费 | 241篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 167篇 |
妇产科学 | 32篇 |
基础医学 | 290篇 |
口腔科学 | 96篇 |
临床医学 | 212篇 |
内科学 | 410篇 |
皮肤病学 | 54篇 |
神经病学 | 99篇 |
特种医学 | 199篇 |
外科学 | 339篇 |
综合类 | 38篇 |
预防医学 | 106篇 |
眼科学 | 66篇 |
药学 | 210篇 |
中国医学 | 52篇 |
肿瘤学 | 140篇 |
出版年
2023年 | 20篇 |
2022年 | 17篇 |
2021年 | 24篇 |
2020年 | 19篇 |
2019年 | 17篇 |
2018年 | 56篇 |
2017年 | 65篇 |
2016年 | 51篇 |
2015年 | 84篇 |
2014年 | 108篇 |
2013年 | 136篇 |
2012年 | 83篇 |
2011年 | 72篇 |
2010年 | 95篇 |
2009年 | 117篇 |
2008年 | 72篇 |
2007年 | 78篇 |
2006年 | 90篇 |
2005年 | 66篇 |
2004年 | 68篇 |
2003年 | 43篇 |
2002年 | 46篇 |
2001年 | 43篇 |
2000年 | 33篇 |
1999年 | 50篇 |
1998年 | 112篇 |
1997年 | 95篇 |
1996年 | 106篇 |
1995年 | 64篇 |
1994年 | 85篇 |
1993年 | 46篇 |
1992年 | 43篇 |
1991年 | 46篇 |
1990年 | 29篇 |
1989年 | 47篇 |
1988年 | 40篇 |
1987年 | 42篇 |
1986年 | 38篇 |
1985年 | 35篇 |
1984年 | 20篇 |
1983年 | 15篇 |
1982年 | 26篇 |
1981年 | 18篇 |
1980年 | 19篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 11篇 |
1976年 | 15篇 |
1975年 | 19篇 |
1972年 | 2篇 |
排序方式: 共有2543条查询结果,搜索用时 46 毫秒
121.
122.
G Lavie ; Y Mazur ; D Lavie ; AM Prince ; D Pascual ; L Liebes ; B Levin ; D Meruelo 《Transfusion》1995,35(5):392-400
123.
124.
Piero Ruggenenti Barbara Ruggiero Paolo Cravedi Marina Vivarelli Laura Massella Maddalena Marasà Antonietta Chianca Nadia Rubis Bogdan Ene-Iordache Michael Rudnicki Rosa Maria Pollastro Giovambattista Capasso Antonio Pisani Marco Pennesi Francesco Emma Giuseppe Remuzzi 《Journal of the American Society of Nephrology : JASN》2014,25(4):850-863
The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic, multicenter, off-on trial (ClinicalTrials.gov #) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ≥2 recurrences over the previous year and were in steroid-induced remission for ≥1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m2 intravenously). At 1 year, all patients were in remission: 18 were treatment-free and 15 never relapsed. Compared with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median number of relapses decreased from 2.5 (interquartile range [IQR], 2–4) to 0.5 (IQR, 0–1; P<0.001) during 1 year of follow-up. Reduction was significant across subgroups (children, adults, MCD/MesGN, and FSGS; P<0.01). After rituximab, the per-patient steroid maintenance median dose decreased from 0.27 mg/kg (IQR, 0.19–0.60) to 0 mg/kg (IQR, 0–0.23) (P<0.001), and the median cumulative dose to achieve relapse remission decreased from 19.5 mg/kg (IQR, 13.0–29.2) to 0.5 mg/kg (IQR, 0–9.4) (P<0.001). Furthermore, the mean estimated GFR increased from 111.3±25.7 to 121.8±29.2 ml/min per 1.73 m2 (P=0.01), with the largest increases in children and in FSGS subgroups. The mean height z score slope stabilized in children (P<0.01). Treatment was well tolerated. Rituximab effectively and safely prevented recurrences and reduced the need for immunosuppression in steroid-dependent or frequently relapsing nephrotic syndrome, and halted disease-associated growth deficit in children.Idiopathic nephrotic syndrome (NS) in children and young adults is almost invariably the clinical counterpart of a continuum of glomerular diseases ranging from the relatively frequent minimal change disease (MCD) and the less frequent mesangial proliferative GN (MesGN), which are predominantly observed in children, to the relatively uncommon FSGS that is observed more frequently in adult patients. NCT009818381 In a small minority of patients that are generally resistant to immunosuppressive therapies, the disease is due to molecular defects of one of the podocyte genes.2 In all of the other cases, it appears to be immune-mediated, but the pathophysiologic process underlying glomerular injury remains poorly understood.3Independent of the underlying renal pathology, prednisone continues to be the cornerstone treatment at disease onset, achieving remission within 4 weeks in approximately 90% of children with MCD and in 20%–60% of those with FSGS.4,5 However, 60%–70% of patients relapse after steroid tapering or withdrawal, and most require repeat courses of prednisone to achieve remission of recurrent episodes and/or the addition of other immunosuppressive medications, such as calcineurin inhibitors, mycophenolate mofetil, or alkylating agents, to reduce the number of relapses and prevent major side effects of steroid treatment.6 According to their relapse rate, these patients are classically labeled as “steroid-dependent” or “frequently relapsing”. In these patients, serious adverse effects of treatment associate with complications of relapsing episodes of heavy proteinuria. These are the patients in most urgent need of more effective and safer treatment.The possibility of a specific and, hopefully, safer approach to patients with steroid-dependent or frequently relapsing NS emerged in 2004 when the B cell–depleting mAb rituximab was reported to induce remission of proteinuria in a child with frequently relapsing NS secondary to MCD who had received this medication to cure a supervened idiopathic thrombocytopenic purpura.7 Subsequent uncontrolled observations found some effect of rituximab in patients with steroid-dependent or frequently relapsing MCD,8–11 suggesting that B-cell immunity could play a key role in the pathophysiology of the disease. Controlled studies in support of this hypothesis, however, have been both scanty and almost confined to children12,13 or to patients with MCD who were evaluated in the context of a retrospective, observational design.14 Indeed, less attention was given to adults and patients with FSGS given difficulties in designing adequately powered trials.Here, we designed a longitudinal, off-on study (ClinicalTrials.gov #) to evaluate the efficacy of rituximab in reducing the incidence of relapses and need for steroid and other immunosuppressive medications in children and adults with steroid-dependent or frequently relapsing NS due to MCD, MesGN, or FSGS. To minimize the side effects and costs of rituximab, we abandoned the standard four-dose protocol originally implemented for the treatment of B-cell lymphomas, NCT0098183815 and adopted a new B cell–driven regimen we found to achieve remission of NS in patients with idiopathic membranous nephropathy (IMN) as effectively as the standard protocol, but with fewer side effects and less costs.16 相似文献
125.
126.
127.
Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies 总被引:6,自引:7,他引:6
Bi L; Sarkar R; Naas T; Lawler AM; Pain J; Shumaker SL; Bedian V; Kazazian HH Jr 《Blood》1996,88(9):3446-3450
128.
Maternal administration of granulocyte colony-stimulating factor improves neonatal rat survival after a lethal group B streptococcal infection 总被引:2,自引:0,他引:2
Novales JS; Salva AM; Modanlou HD; Kaplan DL; del Castillo J; Andersen J; Medlock ES 《Blood》1993,81(4):923-927
Maternally administered recombinant human granulocyte colony- stimulating factor (rhG-CSF) has been shown to cross the placenta and induce a peripheral neutrophilia and increases in the marrow and spleen neutrophil storage pools in fetal and newborn rats. In the present study, we have used this model system to investigate the efficacy of prenatally administered rhG-CSF on neonatal defense to a lethal challenge with Group B-beta hemolytic Streptococcus (GBS). Pregnant rats were injected with rhG-CSF twice daily beginning 6 days before parturition. At birth, all pups were infected with a dose of GBS that is lethal for 90% of infected pups (LD90). Survival was monitored daily for 5 days. Survival of infected pups from saline-treated mothers beyond 60 hours after infection was 10%. No difference in survival was observed among pups from mothers treated 2 and 4 days before parturition. In contrast, we determined that survival was 82.5% among infected pups from mothers treated for 6 days before parturition with rhG-CSF. Our results demonstrate that maternal administration of rhG- CSF augments neonatal defenses against a lethal bacterial challenge. 相似文献
129.
In order to study the pattern of B cell involvement in acute nonlymphocytic leukemia (ANLL), multiple B lymphoid cell lines were established by Epstein-Barr virus transformation of peripheral blood mononuclear cells from two patients with the disease who were heterozygous for the X chromosome-linked glucose-6-phosphate dehydrogenase (G6PD). In one patient, the progenitor cells involved by the leukemia exhibited multipotent differentiative expression, whereas in the other patient the cells showed differentiative expression restricted to the granulocytic pathway. In the patient whose abnormal clone showed multipotent expression, the ratio of B-A G6PD in B lymphoid cell lines was skewed in the direction of type B (the enzyme characteristic of the leukemia clone) and significantly different from the 1:1 ratio expected. It is, therefore, likely that the neoplastic event occurred in a stem cell common to the lymphoid series as well as to the myeloid series. In contrast, evidence for B cell involvement was not detected in the patient whose ANLL progenitor cells exhibited restricted differentiative expression. These findings underscore the heterogeneity of ANLL. Clinically and morphologically similar malignancies in these two patients originated in progenitors with different patterns of stem cell differentiative expression. This difference may reflect differences in cause and pathogenesis. 相似文献
130.
de Koning JP; Dong F; Smith L; Schelen AM; Barge RM; van der Plas DC; Hoefsloot LH; Lowenberg B; Touw IP 《Blood》1996,87(4):1335-1342